. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Cancer Prev Res (Phila). 2011 Sep 19;4(12):2072–2082. doi: 10.1158/1940-6207.CAPR-11-0300

Table 5.

Association of aspirin treatment with risk of adenoma recurrence stratified by ODC genotypes, Aspirin/Folate Polyp Prevention Study, 1994–2001

		[# controls / # cases] RR (95% CI)

SNP		Placebo		81 mg/day Aspirin		325 mg/day Aspirin		P_int
rs2430420
	GG	[58/58]	1.0 (referent)	[76/40]	0.68 (0.50–0.94)	[75/50]	0.81 (0.61–1.09)
	GA/AA	[70/67]	1.0 (referent)	[85/70]	0.95 (0.75–1.20)	[58/85]	1.22 (0.98–1.53)	0.06
rs28362380
	TT	[98/106]	1.0 (referent)	[136/84]	0.75 (0.61–0.92)	[105/110]	0.97 (0.80–1.18)
	TC/CC	[30/19]	1.0 (referent)	[24/26]	1.32 (0.85–2.06)	[28/25]	1.24 (0.80–1.94)	0.06
rs2302615^a
	GG	[72/59]	1.0 (referent)	[78/65]	0.97 (0.75–1.25)	[71/76]	1.11 (0.87–1.42)
	AG/AA	[49/64]	1.0 (referent)	[75/44]	0.65 (0.47–0.88)	[54/58]	0.96 (0.73–1.26)	0.25

Abbreviations: SNP, single nucleotide polymorphism; RR, relative risk; CI, confidence interval; P_int = P for interaction (between aspirin treatment and genotype, modeled dominantly).

Previously genotyped SNP(17).